309 related articles for article (PubMed ID: 15189041)
1. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041
[TBL] [Abstract][Full Text] [Related]
2. Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity.
Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
Peptides; 2005 May; 26(5):887-91. PubMed ID: 15808919
[TBL] [Abstract][Full Text] [Related]
3. Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.
Isfort RJ; Wang F; Tscheiner M; Donnelly E; Bauer MB; Lefever F; Hinkle RT; Mazur AW
J Med Chem; 2005 Jan; 48(1):262-5. PubMed ID: 15634020
[TBL] [Abstract][Full Text] [Related]
4. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
5. Common and divergent structural features of a series of corticotropin releasing factor-related peptides.
Grace CR; Perrin MH; Cantle JP; Vale WW; Rivier JE; Riek R
J Am Chem Soc; 2007 Dec; 129(51):16102-14. PubMed ID: 18052377
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
Cervini L; Theobald P; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1999 Feb; 42(4):761-8. PubMed ID: 10052982
[TBL] [Abstract][Full Text] [Related]
7. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
[TBL] [Abstract][Full Text] [Related]
8. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
9. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
[TBL] [Abstract][Full Text] [Related]
10. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
[TBL] [Abstract][Full Text] [Related]
11. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
Klose J; Fechner K; Beyermann M; Krause E; Wendt N; Bienert M; Rudolph R; Rothemund S
Biochemistry; 2005 Feb; 44(5):1614-23. PubMed ID: 15683245
[TBL] [Abstract][Full Text] [Related]
12. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
[TBL] [Abstract][Full Text] [Related]
13. Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions.
Hinkle RT; Donnelly E; Cody DB; Samuelsson S; Lange JS; Bauer MB; Tarnopolsky M; Sheldon RJ; Coste SC; Tobar E; Stenzel-Poore MP; Isfort RJ
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E889-98. PubMed ID: 12959937
[TBL] [Abstract][Full Text] [Related]
14. Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies.
Lovejoy DA; Rotzinger S; Barsyte-Lovejoy D
Ann N Y Acad Sci; 2009 Apr; 1163():215-20. PubMed ID: 19456342
[TBL] [Abstract][Full Text] [Related]
15. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
Dautzenberg FM; Py-Lang G; Higelin J; Fischer C; Wright MB; Huber G
J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
[TBL] [Abstract][Full Text] [Related]
16. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
[TBL] [Abstract][Full Text] [Related]
17. Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues.
Kraetke O; Holeran B; Berger H; Escher E; Bienert M; Beyermann M
Biochemistry; 2005 Nov; 44(47):15569-77. PubMed ID: 16300406
[TBL] [Abstract][Full Text] [Related]
18. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
Tsatsanis C; Androulidaki A; Dermitzaki E; Gravanis A; Margioris AN
J Cell Physiol; 2007 Mar; 210(3):774-83. PubMed ID: 17117478
[TBL] [Abstract][Full Text] [Related]
19. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J
J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886
[TBL] [Abstract][Full Text] [Related]
20. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates.
Lovejoy DA; Balment RJ
Gen Comp Endocrinol; 1999 Jul; 115(1):1-22. PubMed ID: 10375459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
